Navigation Links
CRF announces late breaking trials to be presented at TCT 2009 in San Francisco
Date:8/12/2009

WHAT:

The Cardiovascular Research Foundation has announced the late breaking trials that will be presented at TCT (Transcatheter Cardiovascular Therapeutics) 2009, the largest global medical and scientific symposium dedicated to interventional cardiovascular medicine.

TCT 2009 will also feature a new session on Electronic Medical Records (EMR). Leading experts will discuss the latest developments in EMR and its relevance to health care reform.

WHEN:

The TCT Scientific Symposium will be held September 21-25, 2009.

Late-breaking clinical trials will be highlighted during press conferences scheduled for Wednesday, September 23, Thursday, September 24, and Friday, September 25.

WEDNESDAY, SEPTEMBER 23

SPIRIT IV: A Prospective Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

COMPARE: A Prospective Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

ISAR-DESIRE 2: A Prospective Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Sirolimus-Eluting Stent Restenosis

SIRTAX-LATE: Five-Year Clinical and Angiographic Follow-up from a Prospective Randomized Trial of Paclitaxel-Eluting and Sirolimus-Eluting Stents

LEADERS: Two-Year Follow-up from a Prospective Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer

FAME: Two-Year Follow-up from a Prospective Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease

THURSDAY, SEPTEMBER 24

CURRENT-PCI OASIS 7: A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS

COGENT: A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel

CHARISMA GENOMICS SUBSTUDY: Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention

TRITON-TIMI 38 ECONOMIC SUBSTUDY: Cost-Effectiveness of Prasugrel vs. Clopidogrel from a Prospective Randomized Trial of Patients with ACS Undergoing PCI

PLATO INVASIVE: A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy

PROSPECT: A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque

FRIDAY, SEPTEMBER 25

SYMPLICITY I: One-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension

DEBATER: A Prospective Randomized Trial of Drug-Eluting vs. Bare-Metal Stents With or Without Abciximab in STEMI

HORIZONS AMI: Two-Year Follow-up from a Prospective Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare-Metal Stents in STEMI

BCIS-1: A Prospective Randomized Trial of Intra-Aortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI

NORDIC-BALTIC BIFURCATION STUDY III: A Prospective Randomized Trial of Side Branch Dilatation Strategies in Patients with Coronary Bifurcation Lesions Undergoing Treatment with a Single Stent

FAUST: A Prospective Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access

WHERE:

The Moscone Center
San Francisco, CA

HOW TO REGISTER:

Media may apply for registration by clicking on: http://www.tctconference.com/press/press-registration/press-pre-registration.html

Details on required press credentials can be found at: http://www.tctconference.com/press/press-policies.html


'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma
2. Preferred Health Technology Announces Support for MGMAs Project SwipeIT
3. International Isotopes Inc. Announces Second Quarter and Six Months 2009 Financial Results
4. Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured
5. Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
6. Beckman Coulter Announces the Creation of Beckman Coulter Genomics
7. The Brain Aneurysm Foundation Announces Six Grants to Further Treatment for Brain Aneurysms
8. Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R)
9. 3SBio Inc. Announces Unaudited Second Quarter 2009 Results
10. Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results
11. Webmedx Announces That CEO Sean Carroll Has Been Appointed to the AHIMA Foundation Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... 08, 2016 , ... With the increasing demand for dental implants, the National ... campaign to inform dentists and patients about the safety issues related to dental restorations. ... in the U.S. is projected to reach $6.4 billion in 2018 with more than ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... for customers and employees that are both engaging and easy to use. Coming ... Technology, the software company revealed today its plans to roll out new AI-powered ...
(Date:12/8/2016)... ... , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services from ... Messina. , Among the recognitions, the American College of Surgeons' (ACS) named the ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... soon after surgery as possible. With this in mind, SIGVARIS has created a ... or blood clot) during bed rest and provide the benefits of graduated compression ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... -- Mitsubishi Tanabe Pharma Corporation (Head Office: ... Masayuki Mitsuka ) has presented data that show ... in 10-14 day cycles for 48 weeks experienced significantly ... Rating Scale-Revised (ALSFRS-R). The data were presented at the ... Dublin, Ireland . In the ...
(Date:12/9/2016)... HARRISBURG, Pa. , Dec. 9, 2016 ... today announced temporary regulations for medical marijuana dispensaries under ... The Pennsylvania Bulletin , and are now available ... what is needed in the plan for operation; process ... the dispensary; as well as where the dispensary facilities ...
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 ... Market Outlook to 2022", provides key market data on ... in millions of US dollars, volume (in units) and ... Femtosecond Lasers and YAG Lasers. The report also ... of these market segements, and global corporate-level profiles of ...
Breaking Medicine Technology: